To the Editor

We read with interest the report by Davido et al.,\[[@bib1]\] in which the authors described a subset of COVID-19 patients in the Paris-Ile-de-France area with persistent symptoms at least two months after SARS-CoV-2 infection characterized by fatigue, myalgias, subjective fevers, headaches, and symptoms of autonomic impairment. The authors hypothesize that these symptoms represent a post-viral syndrome that requires no specific treatment, possibly related to microangiopathy and endothelial injury in susceptible patients.

We too have observed that a subset of individuals with COVID-19 may develop a chronic condition that persists well after initial presentation, with prominent fatigue, cognitive slowing, and symptoms of autonomic impairment such as orthostatic intolerance, exaggerated postural tachycardia, and episodic hyperadrenergic surges; however, we disagree that these sequelae require no specific treatment. On the contrary, there are several treatment paradigms to consider for such patients with precedent in the autonomic literature, including fluid and salt loading,\[[@bib2]\] graduated exercise therapy starting in a reclined position,\[[@bib2]\] and targeted pharmacological treatment\[[@bib3]\] for symptomatic improvement, depending on the symptom complex. In addition, post-viral autonomic impairment may have an autoimmune basis, and in some cases is amendable to immunotherapy \[[@bib4],[@bib5]\].

Non-pharmacologic and symptomatic pharmacologic treatments are commonly used to treat postural orthostatic tachycardia syndrome (POTS) and orthostatic intolerance (OI), common autonomic disorders that are frequently reported after viral infection \[[@bib6],[@bib7]\]. While we have observed many phenotypic similarities between POTS, OI and the post-viral syndrome that appears in some COVID-19 patients, presenting, as the authors observe, in women ages 40 and younger, there may be significant clinical variation in such patients, and further research is necessary to confirm and further characterize these initial reports. While at the moment there is no universal treatment protocol, it should be emphasized that treatment does exist for post-viral autonomic impairment, and has the potential to reduce symptom burden and improve quality-of-life in affected patients. However, it should be noted that while these treatment recommendations are based on evidence supported by studies on patients with POTS, there are no such studies in patients with autonomic impairment secondary to COVID-19. Thus, prospective longitudinal studies are needed the quantify the symptom burden in those with persistent symptoms, and more importantly evaluate the response to these and other potential therapies.
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